ACU Acumentis Group Limited

Avantogen (ASX:ACU) today announced the acceptance of a scientific paper entitled, "Synergistic Effects of Immune Agonists on Efficacy of Vaccines" for the 20th Annual Meeting of the International Society for Biological Therapy of Cancer. The meeting will be held November 11 - 13, 2005, at the Hilton Alexandria Mark Center, Alexandria, VA, and focuses on the prevailing issues in immunology and biological therapy of cancer. Dante Marciani, Ph.D., Avantogen's Chief Scientist, Immunotherapy, will present the Poster to the attending scientists. The abstract of the presentation will be published in the November/December 2005 issue of the Journal of Immunotherapy. Avantogen CEO, Dr. Leonard Firestone, observed: "GPI-0100, a saponin derivative, is an extremely effective, non-toxic, highly stable immune booster that demonstrably improves the immune response to antigens in a great variety of vaccines (for example, see Slovin et al's publication in the January 2005 issue of Vaccine). The head of Avantogen's programs, Dr. Marciani, is a world authority on vaccine agonist structure-activity relations, as well as GMP manufacture. Dr. Marciani has recently overseen our Company's involvement in several human cancer vaccine trials, and is now broadening GPI-0100's application to infectious disease vaccines as well. Dr. Marciani and Avantogen are actively seeking new collaborations with both types of vaccine developers/manufacturers. This acceptance by a peer review conference further validates our confidence in this adjuvant." About Avantogen Avantogen (formerly Australian Cancer Technology) is an international biotechnology company developing a broad oncology-related product portfolio. Avantogen is developing RP101, an exceptionally promising pancreatic cancer drug currently in Phase II clinical studies, through a joint venture with Bioaccelerate of New York. Avantogen's Pentrys(TM) anti-cancer vaccine is undergoing Phase IIb clinical trials in prostate cancer patients, and the Company is advancing a family of immune-enhancing adjuvants which has been in three Phase I cancer trials in the United States. The company has also marketed Revisys(TM), a branded line of medical nutritionals specifically developed to address special nutritional needs, such as those following cancer treatments. Avantogen is traded on the Australian Stock Exchange (ASX) under the symbol ACU. The Company has established a Level 1 ADR stock program in the U.S. trading under the symbol AUCJY and also is listed on the Xetra exchange, the electronic trading system of the Frankfurt Stock Exchange, trading under the symbol CBS. Forward-Looking Statements Statements contained in this press release that are not historical information are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties that could cause Avantogen's ("company") actual results to differ materially from those projected or implied. Such potential risks and uncertainties relate, but are not limited, to the results of clinical trials, product demand and market acceptance, the impact of competitive products and pricing, effectiveness and pace of current and future product development, and regulatory approval. More detailed information on these and additional factors that could affect the company's operating and financial results are described in the company's annual reports filed or to be filed with the Australian Stock Exchange. The company urges all interested parties to read these reports to gain a better understanding of the many business and other risks that the company faces. The historical results achieved by the company are not necessarily indicative of its future prospects. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.